2. Sorokin I., Mamoulakis C., Miyazawa K., Rodgers A., Talati J., Lotan Y.Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301–1320.

3. Djavadzade S.M. Urinary stone disease in endemic region: etiology, pathogenesis, symptoms, treatment. Diss..., d-ra med nauk, M., 1997. Russian (Джавад-заде С.М. Мочекаменная болезнь в эндемическом регионе: этиопатогенез, клиника, лечение. Дисс. докт. мед. наук.М., 1997).

4. Konstantinova O.V. Prediction and principles of prevention of urinary stone disease. Diss..., d-ra med nauk, M.,1999. Russian (Константинова О.В.Прогнозирование и принципы профилактики мочекаменной болезни. Дисс д-ра мед. наук, М., 1999).

5. Daudon M., Doré J.-C., Jungers P., Lacour B. Changes in stone composition according to age and gender of patients: a multivariate epidemiological approach. Urol. Res. 2004;32,:241–247.

6. Adair L.S., Popkin B.M. Are child eating patterns being transformed globally? Obes Res. 2005;13:1281–1299.

7. Lotan Y., Antonelli J., Jimйnez I.B., Gharbi H., Herring R., Beaver A., Denni A.,Von Merveldt D., Carter S., Cohen A., Poindexter J., Moe O.W.,. Pearle M.S The kidney stone and increased water intake trial in steel workers: results from a pilot study. Urolithiasis 2016. Doi 10.1007/s00240-016-0892207.

8. Marangella M. Use of citrate in patients with nephrolithiasis. G. Ital. Nefrol. 2017;34(4):51–60. PMID: 28762682.

9. Tracy C.R., Pearle M.S. Update on the medical management of stone disease. Curr Opin Urol. 2009;19(2): 200–204.

10. Baumann J.M., Affolter B., Caprez U., Clivaz C., von Arx U. Role of calcium in the aggregation of particles coated by urinary macromolecules. Urol Int 2009;82:459–463.

11. Chemistry and life. 1994, № 1. Russian (Химия и жизнь. 1994. № 1).

12. Pytel’ Yu.A., Zolotarev I.I. Uric acid kidney stones. 1995, p. 23–24. Russian (Пытель Ю.А. Золотарев И.И. Уратный нефролитиаз. 1995. С. 23–24).

13. Johnson R.J., Titte S., Cade J.R., Rideout B.A., Oliver W.J. Uric acid, evolution and primitive cultures. Semin Nephrol. 2005;25:3–8.

14. Emmerson B.T., Gordon R.B., Johnson L.A. Urate Kinetics in Hypoxanthine – guanine Phosphoribosyltransferase Deficiency: Their Significance for the Understanding of Gout. Quart. J. Med. 1976;45:49–61.

15. Pak C.Y., Sakhaee K., Peterson R.D., Poindexter J.R., Frawley W.H. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney international. 2001;60(2):757–761.

16. Alvarez-Nemegyei J., Medina-Escobedo M., Villanueva-Jorge S., Vazquez-Mellado J. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? J Rheumatol. 2005;32(11):2189–2191.

17. Curhan G.C., Taylor E.N. 24-h uric acid excretion and the risk of kidney stones. Kidney international. 2008;73(4):489-96.

18. Sakhaee K., Adams-Huet B., Moe O.W., Pak C.Y. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney international. 2002;62(3):971–979.

19. Eisenberg H., Connor T.B., Howard J.E. A useful agent for oral alkali therapy. The Journal of clinical endocrinology and metabolism. 1955;15(4):503–505. Doi: 10.1210/jcem-15-4-503.

20. Maalouf N.M. et al. Metabolic basis for low urine pH in type 2 diabetes.Clin J Am Soc Nephrol. 2010;5(7):1277–1281.

21. Lieske J.C. et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis. 2006;48(6):897–904.

22. Kocvara R., Louzensky G., Ptacek V. Detection of metabolic disorders as a cause of urolithiasis in clinical practice. Cas Lek Ctsk. 1989;128(10):295–298.

23. Hinck B.D., Ganesan V., Tarplin S., Asplin J., Granja I., Calle J., Sivalingam S., Monga M. Can a Simplified 12-Hour Nighttime Urine Collection Predict Urinary Stone Risk? Urology. 2017;108:40–45.

24. Saenko V.S., Gazimiev M.A., Pesegov S.V. The place of mineral water for the recurrence prevention of urolithiasis. Urologiia. 2016;S2:87–94. Russian (Саенко В.С., Газимиев М.А., Песегов С.В. Место минеральных вод в метафилактике мочекаменной болезни. Урология. 2016;S2:87–94).

25. Touhami M. et al. Lemon juice has protective activity in a rat urolithiasis model. BMC Urology 2007:18 https://doi.org/10.1186/1471-2490-7-18

26. Grases F. et al. Phytotherapy and renal stones: the role of antioxidants.A pilot study in Wistar rats Urol Res 2009;37:35–40. Doi: 10.1007/s00240-008-0165-1.

27. Siddiquia W.A., Shahzada M., Shabbirb A., Ahmadc A. Evaluation of anti-urolithiatic and diuretic activities of watermelon (Citrullus lanatus) using in vivo and in vitro experiments. Biomedicine & Pharmacotherapy 97. 2018;1212–1221.

28. Birowo P., Widyahening I.S. Effect of citrus-based products on urine profile: A systematic review and meta-analysis. Nur Rasyid. 2017;6:220. Doi: 10.12688/f1000research.10976.1.

29. Fakhoury M.Q., Gordon B., Shorter B., Renson A., Borofsky M.S., Cohn M.R.,Cabezon E., Wysock J.S., Bjurlin M.A. Perceptions of dietary factors promoting and preventing nephrolithiasis: a cross-sectional survey. World J Urol. 2018. Doi: 10.1007/s00345-018-2562-6.

30. Türk C., Neisius A., Petrik A., Seitz C., Skolarikos A., Tepeler A., Thomas K. EAU guidelines on urolithiasis. 2017.

31. Rapoport L.M., Tsarichenko D.G., Saenko V.S., Frolova E.A. Opportunities of citrate therapy in patients with urinary stone disease. Farmateka. 2016;s1:40–43. Russian (Рапопорт Л.М., Цариченко Д.Г., Саенко В.С., Фролова Е.А. Возможности цитратной терапии в лечении пациентов с мочекаменной болезнью. Фарматека. 2016;s1:40–43).